Norbert Pardi
Norbert Pardi
Verified email at
Cited by
Cited by
mRNA vaccines—a new era in vaccinology
N Pardi, MJ Hogan, FW Porter, D Weissman
Nature reviews Drug discovery 17 (4), 261-279, 2018
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
N Pardi, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, ...
Nature 543 (7644), 248-251, 2017
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
N Pardi, S Tuyishime, H Muramatsu, K Kariko, BL Mui, YK Tam, ...
Journal of Controlled Release 217, 345-351, 2015
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses
N Pardi, MJ Hogan, MS Naradikian, K Parkhouse, DW Cain, L Jones, ...
Journal of Experimental Medicine 215 (6), 1571-1588, 2018
Recent advances in mRNA vaccine technology
N Pardi, MJ Hogan, D Weissman
Current opinion in immunology 65, 14-20, 2020
D614G spike mutation increases SARS CoV-2 susceptibility to neutralization
D Weissman, MG Alameh, T de Silva, P Collini, H Hornsby, R Brown, ...
Cell host & microbe 29 (1), 23-31. e4, 2021
SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation
K Lederer, D Castańo, DG Atria, TH Oguin, S Wang, TB Manzoni, ...
Immunity 53 (6), 1281-1295. e5, 2020
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
N Pardi, AJ Secreto, X Shan, F Debonera, J Glover, Y Yi, H Muramatsu, ...
Nature communications 8 (1), 14630, 2017
A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice
D Laczkó, MJ Hogan, SA Toulmin, P Hicks, K Lederer, BT Gaudette, ...
Immunity 53 (4), 724-732. e7, 2020
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
MG Alameh, I Tombácz, E Bettini, K Lederer, S Ndeupen, C Sittplangkoon, ...
Immunity 54 (12), 2877-2892. e7, 2021
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
N Pardi, K Parkhouse, E Kirkpatrick, M McMahon, SJ Zost, BL Mui, ...
Nature communications 9 (1), 3361, 2018
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
T Rothgangl, MK Dennis, PJC Lin, R Oka, D Witzigmann, L Villiger, W Qi, ...
Nature biotechnology 39 (8), 949-957, 2021
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
KO Saunders, E Lee, R Parks, DR Martinez, D Li, H Chen, RJ Edwards, ...
Nature 594 (7864), 553-559, 2021
A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice
AW Freyn, JR da Silva, VC Rosado, CM Bliss, M Pine, BL Mui, YK Tam, ...
Molecular Therapy 28 (7), 1569-1584, 2020
In vitro transcription of long RNA containing modified nucleosides
N Pardi, H Muramatsu, D Weissman, K Karikó
Synthetic Messenger RNA and Cell Metabolism Modulation: Methods and …, 2013
The transcription factor T-bet resolves memory B cell subsets with distinct tissue distributions and antibody specificities in mice and humans
JL Johnson, RL Rosenthal, JJ Knox, A Myles, MS Naradikian, J Madej, ...
Immunity 52 (5), 842-855. e6, 2020
HPLC purification of in vitro transcribed long RNA
D Weissman, N Pardi, H Muramatsu, K Karikó
Synthetic messenger RNA and cell metabolism modulation: Methods and …, 2013
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
DR Martinez, A Schäfer, SR Leist, G De la Cruz, A West, ...
Science 373 (6558), 991-998, 2021
mRNA vaccines in the COVID-19 pandemic and beyond
MJ Hogan, N Pardi
Annual review of medicine 73, 17-39, 2022
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
CP Arevalo, MJ Bolton, V Le Sage, N Ye, C Furey, H Muramatsu, ...
Science 378 (6622), 899-904, 2022
The system can't perform the operation now. Try again later.
Articles 1–20